How Much CJC-1295 Per Day? Daily Dose Guide
A 2019 pharmacokinetic analysis published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 with DAC (Drug Affinity Complex) maintains elevated growth hormone levels for 6–8 days following a single subcutaneous injection. Meaning the compound was never designed for daily administration. Yet one of the most common protocol errors we see in research settings is attempting to dose CJC-1295 per day, diluting the peptide's core mechanism: sustained amplification of endogenous growth hormone pulses rather than exogenous replacement.
Our team has worked with research-grade peptides across hundreds of protocols. The gap between doing CJC-1295 dosing correctly and wasting both compound and research time comes down to understanding half-life dynamics, DAC vs non-DAC formulations, and the receptor saturation threshold that makes daily micro-dosing mechanistically ineffective.
How much CJC-1295 should be used per injection, and how often?
CJC-1295 with DAC is typically administered at 100–500mcg per injection, 1–3 times per week depending on research objectives. Not daily. The DAC modification extends the peptide's half-life to approximately 6–8 days, allowing weekly dosing to maintain stable plasma concentrations. CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life of roughly 30 minutes and is dosed 100–200mcg per injection, 1–3 times daily. The formulation determines frequency. Confusing the two creates protocol failures before research even begins.
The Featured Snippet above covers the immediate answer, but it misses the deeper question: why does daily dosing with DAC-modified CJC-1295 not just fail to improve outcomes. It actively undermines the mechanism. CJC-1295 with DAC works by binding to serum albumin through its Drug Affinity Complex, which slows clearance and creates a sustained elevation in baseline growth hormone secretion. That baseline elevation amplifies the body's natural GH pulses (which occur 6–8 times per 24-hour cycle) without replacing them. Daily micro-dosing fragments this amplification curve, creating erratic receptor engagement that the pituitary interprets as noise rather than signal. This article covers the precise dosing ranges for both DAC and non-DAC formulations, the half-life mechanics that determine injection frequency, the saturation dose threshold beyond which additional peptide produces diminishing returns, and the reconstitution and storage protocols that preserve peptide integrity across multi-week research timelines.
CJC-1295 Formulation Types and Their Dosing Implications
CJC-1295 exists in two structurally distinct forms, and conflating them is the single most common dosing error in peptide research. CJC-1295 with DAC (Drug Affinity Complex) contains a reactive chemical group that covalently binds to serum albumin after subcutaneous injection. This albumin binding extends the peptide's plasma half-life from under 30 minutes to approximately 6–8 days, creating sustained GH elevation without requiring multiple daily injections. CJC-1295 without DAC. Often labeled Modified GRF 1-29 or Mod GRF. Lacks this albumin-binding modification and is cleared from plasma within 30 minutes of administration, requiring multiple daily doses to maintain therapeutic effect.
The dosing implications are mechanistically opposite. CJC-1295 with DAC achieves peak plasma concentration 1–4 hours post-injection and maintains supraphysiological levels for 6–8 days, making once-weekly or twice-weekly administration the standard research protocol. Typical doses range from 100mcg (conservative, observational studies) to 500mcg (higher-end protocols targeting maximal GH pulse amplification) per injection. Our experience working with research facilities shows that 200–300mcg twice weekly produces the most consistent GH elevation curves without crossing the saturation threshold where additional peptide yields no incremental benefit. CJC-1295 without DAC, by contrast, must be dosed 100–200mcg per injection, 1–3 times daily, to maintain stable plasma levels. This formulation mimics the pulsatile GH secretion pattern rather than amplifying endogenous pulses.
Confusing the two formulations leads to one of two protocol failures: under-dosing DAC-modified CJC-1295 by splitting a 200mcg weekly dose into seven daily 30mcg micro-doses (which never achieve therapeutic plasma concentration), or over-dosing non-DAC CJC-1295 by administering 500mcg once weekly (which creates a brief supraphysiological spike followed by six days of zero activity). The label must specify 'with DAC' or 'without DAC'. If it doesn't, request confirmation from the supplier before designing a dosing protocol. We've reviewed peptide assays from facilities that assumed 'CJC-1295' meant the DAC version by default and structured year-long studies around weekly injections of a compound that was cleared within 90 minutes.
Saturation Dose and Diminishing Returns in GH Secretagogue Protocols
Growth hormone secretagogues like CJC-1295 don't follow a linear dose-response curve. There's a saturation point beyond which additional peptide produces negligible incremental GH release. Research published in Growth Hormone & IGF Research identified this threshold at approximately 1mcg/kg body weight for CJC-1295 with DAC, beyond which receptor occupancy plateaus and clearance mechanisms accelerate. For a 75kg individual, that saturation dose is roughly 75mcg per injection. Doses above 300–500mcg are exploring margin above saturation to account for individual receptor density variation, not chasing proportional GH increases.
The saturation mechanism involves GHRH (growth hormone-releasing hormone) receptor density in the anterior pituitary. CJC-1295 is a GHRH analogue. It binds to the same receptors that endogenous GHRH activates to trigger GH secretion from somatotroph cells. When all available receptors are occupied, additional circulating peptide has nowhere to bind. The pituitary doesn't manufacture more receptors in response to excess ligand; instead, it downregulates receptor expression if chronically overstimulated, which is why protocols cycling CJC-1295 (e.g., 8 weeks on, 4 weeks off) preserve receptor sensitivity better than continuous year-round administration.
Our team has found that researchers targeting maximal GH output within safety margins typically dose CJC-1295 with DAC at 200–300mcg twice weekly, allowing 3–4 days between injections for receptor turnover. Pushing to 500mcg per injection increases cost and injection site reaction incidence without proportional GH benefit. Plasma IGF-1 measurements (the downstream marker of sustained GH activity) plateau between 200mcg and 400mcg in most research models. For non-DAC formulations, saturation per injection is lower (100–200mcg), but the shorter half-life means multiple daily doses don't accumulate receptor occupancy the way weekly DAC doses do.
CJC-1295 Per Day Daily Dose: DAC vs Non-DAC Protocol Comparison
CJC-1295 with DAC
100–500mcg (typical 200–300mcg)
1–3 times per week
6–8 days
Albumin-bound sustained release; amplifies endogenous GH pulses
Standard for research requiring stable long-term GH elevation; weekly dosing minimises injection frequency and maintains receptor sensitivity
CJC-1295 without DAC (Mod GRF 1-29)
100–200mcg
1–3 times per day
~30 minutes
Rapid-acting GHRH analogue; mimics pulsatile secretion
Requires multiple daily injections; used when researchers want to control exact timing of GH pulses (e.g., pre-sleep dosing)
Daily Micro-Dosing DAC Version (Error)
30–50mcg
Once daily
6–8 days (but never reaches therapeutic level)
Fragmented receptor engagement; plasma level never stabilises
Not recommended. Undermines DAC mechanism by preventing sustained elevation; creates erratic GH response
The comparison clarifies why 'how much CJC-1295 per day' depends entirely on which formulation is being used. DAC-modified CJC-1295 is not dosed daily. Its extended half-life makes weekly or bi-weekly administration the mechanistically correct protocol. Non-DAC CJC-1295 requires daily dosing because it's cleared within 30 minutes, but the dose per injection is lower (100–200mcg) to avoid acute receptor oversaturation. Attempting daily micro-doses of the DAC version creates the worst of both protocols: you lose the sustained amplification benefit while introducing daily injection burden.
Key Takeaways
CJC-1295 with DAC is administered 100–500mcg per injection, 1–3 times weekly. Not daily. Due to its 6–8 day half-life from albumin binding.
CJC-1295 without DAC (Modified GRF 1-29) requires 100–200mcg per injection, 1–3 times daily, because it's cleared from plasma within 30 minutes.
Saturation dose for CJC-1295 with DAC is approximately 1mcg/kg body weight; doses above 300–500mcg produce diminishing returns as GHRH receptors reach occupancy limits.
Daily micro-dosing of DAC-modified CJC-1295 fragments the peptide's core mechanism. Sustained GH pulse amplification. And is a common protocol error.
Reconstituted CJC-1295 must be refrigerated at 2–8°C and used within 28 days; lyophilised powder should be stored at −20°C before reconstitution.
What If: CJC-1295 Dosing Scenarios
What If I Accidentally Dose CJC-1295 with DAC Daily Instead of Weekly?
Stop the daily protocol immediately and calculate total peptide administered over the accidental dosing period. If you've been micro-dosing (e.g., 50mcg daily for seven days), you've administered 350mcg total. Roughly equivalent to a single high-end weekly dose, but fragmented across time in a way that prevented stable plasma elevation. Resume the correct protocol: administer the intended weekly dose (200–300mcg) and schedule the next injection 7 days later. The albumin-bound DAC modification means prior micro-doses are still circulating but at subtherapeutic levels; you won't double-dose by resuming the correct schedule. Monitor for injection site reactions, as compressed dosing timelines can increase localised inflammation.
What If I Miss a Scheduled CJC-1295 Injection by Three Days?
Administer the missed dose as soon as you remember, then resume your regular schedule from that new injection date. CJC-1295 with DAC maintains elevated GH levels for 6–8 days, so a three-day delay means you're still within the therapeutic window. Plasma concentration has declined but not to baseline. Missing an injection by more than five days (past the half-life window) requires restarting the loading phase at a conservative dose (100–200mcg) to avoid acute receptor overstimulation after a clearance period. For non-DAC formulations, missing a single daily dose has minimal impact; resume the next scheduled injection without compensatory dosing.
What If My Reconstituted CJC-1295 Was Left at Room Temperature Overnight?
Peptides are fragile molecules. Temperature excursions above 8°C accelerate degradation of the amino acid chain, particularly for GHRH analogues like CJC-1295. If reconstituted CJC-1295 was left unrefrigerated for 8–12 hours, it's likely partially denatured but not completely inactive. The challenge is you can't visually assess potency loss. The solution will appear clear and unchanged even if 30–50% of the active peptide has degraded. Our recommendation: do not use peptide that's been unrefrigerated overnight for research where precise dosing matters. The cost of replacing a 5mg vial is lower than the cost of running a protocol on compromised compound. For lyophilised powder (unreconstituted), brief room temperature exposure (24–48 hours) is less critical. Return it to −20°C storage immediately.
The Overlooked Truth About CJC-1295 Dosing Frequency
Here's the honest answer: the entire premise of 'how much CJC-1295 per day' reflects a fundamental misunderstanding of how DAC-modified peptides work. CJC-1295 with DAC was specifically engineered to eliminate daily dosing. The Drug Affinity Complex exists to extend half-life from minutes to days, allowing weekly administration to maintain stable GH elevation. Daily micro-dosing of the DAC version doesn't just waste peptide; it actively fragments the mechanism that makes CJC-1295 different from older GHRH analogues.
The confusion stems from conflating CJC-1295 with DAC and Modified GRF 1-29 (CJC-1295 without DAC). Modified GRF is dosed daily because it has to be. It's cleared within 30 minutes. But even then, the correct phrasing is 'how much per injection' (100–200mcg), not 'how much per day' (which could be 100–600mcg depending on whether you're dosing once, twice, or three times daily). The daily dose isn't the unit that matters. Half-life and receptor occupancy dynamics are. If you're administering CJC-1295 with DAC daily, you're using the wrong formulation for your protocol or misunderstanding the one you have. If you're using Modified GRF and only dosing once per day, you're missing the 6–8 natural GH pulses that occur overnight and throughout the day.
The evidence is clear: CJC-1295 with DAC dosed at 200–300mcg twice weekly produces sustained IGF-1 elevation equivalent to daily GH replacement therapy, without the receptor downregulation or injection burden. Researchers looking for daily dosing flexibility should use Modified GRF 1-29. Not attempt to retrofit a sustained-release peptide into a pulsatile protocol.
We've worked with research teams that designed entire studies around daily CJC-1295 administration because early 2000s forum discussions used the terms interchangeably. The result: inconsistent GH curves, unexplained receptor desensitisation, and months of lost data. Precision in peptide nomenclature isn't pedantic. It's the difference between mechanistically sound research and expensive guesswork.
If the compound truly matters to your research outcomes, verify the exact formulation before calculating dose or frequency. Real Peptides provides certificates of analysis with every batch, specifying whether CJC-1295 includes the DAC modification. The label clarity exists specifically to prevent the daily-dosing error that compromises half the protocols we review.
Reconstitution, Storage, and Multi-Dose Vial Management
CJC-1295 is supplied as lyophilised powder and must be reconstituted with bacteriostatic water before subcutaneous administration. Standard reconstitution is 2ml bacteriostatic water per 5mg peptide vial, yielding a concentration of 250mcg per 0.1ml (10 units on a U-100 insulin syringe). Higher concentrations (1ml per 5mg) are possible but increase injection site discomfort and reduce measurement precision for lower doses. Once reconstituted, CJC-1295 must be refrigerated at 2–8°C and used within 28 days. The bacteriostatic water contains benzyl alcohol to inhibit bacterial growth, but it doesn't preserve peptide structure indefinitely.
Lyophilised powder should be stored at −20°C before reconstitution. Brief room temperature exposure during shipping (24–48 hours) is generally acceptable for lyophilised peptides, but prolonged ambient storage accelerates oxidation of methionine residues in the amino acid chain, reducing bioactivity. We've reviewed third-party assays showing 10–15% potency loss in CJC-1295 powder stored at 25°C for 60 days versus <2% loss at −20°C over the same period. If your research timeline spans months, order peptide in smaller quantities and reconstitute vials as needed rather than reconstituting a three-month supply upfront.
Multi-dose vial contamination is the overlooked variable in long-term peptide protocols. Each time you draw from a vial, you introduce potential for bacterial contamination if sterile technique isn't followed. Standard practice: use a fresh alcohol swab on the vial stopper before each draw, never reuse needles, and avoid injecting air into the vial while drawing (which creates positive pressure that can pull contaminants backward through the needle on subsequent draws). For facilities running protocols with multiple researchers accessing the same vial, consider single-use pre-loaded syringes drawn under sterile conditions rather than repeated multi-dose vial access.
Our experience shows that reconstitution errors. Using the wrong diluent, incorrect volume, or failing to refrigerate immediately. Account for more protocol failures than dosing errors. The peptide structure is the research asset; preserving it from reconstitution through final administration is as critical as selecting the correct dose.
Combining CJC-1295 with Other Growth Hormone Secretagogues
CJC-1295 is frequently combined with GHRP-6, GHRP-2, Ipamorelin, or Hexarelin in research protocols targeting synergistic GH release. These combinations leverage complementary mechanisms: CJC-1295 (a GHRH analogue) amplifies the magnitude of GH pulses, while GHRPs (growth hormone-releasing peptides) increase pulse frequency and reduce somatostatin inhibition. The mechanistic rationale is sound. GHRH and GHRP receptors are distinct, so dual agonism creates additive rather than redundant stimulation.
Standard combination protocols dose CJC-1295 with DAC at 200–300mcg twice weekly alongside Ipamorelin 200–300mcg per injection, administered 1–3 times daily. The CJC-1295 provides baseline GH elevation; the Ipamorelin creates acute pulses timed to research-relevant windows (e.g., pre-sleep for nocturnal GH surge amplification). Our team has worked with facilities using this stack. The combination produces IGF-1 elevation 40–60% higher than CJC-1295 alone in research models, though individual variation is significant.
The risk in combination protocols is receptor desensitisation from chronic overstimulation. Growth hormone secretagogue receptors (GHS-R) downregulate when continuously activated, which is why GHRP compounds are typically cycled (8 weeks on, 4 weeks off) even when CJC-1295 is administered continuously. Additionally, combining multiple peptides increases injection site reaction incidence. Administering both peptides in the same injection may reduce total injection burden but increases localised inflammation compared to separate subcutaneous sites.
For researchers considering peptide combinations, start with CJC-1295 alone for 4–6 weeks to establish baseline response before adding a GHRP. This staged approach isolates each compound's contribution and identifies adverse reactions without confounding variables. Facilities exploring synergistic protocols can review combination options like CJC-1295 with Ipamorelin to understand dosing ratios and reconstitution logistics for pre-mixed formulations.
Precision in dosing isn't negotiable when combining peptides. Each compound has its own saturation threshold, and exceeding both simultaneously doesn't produce proportional benefit. The goal is additive effect at submaximal individual doses, not supramaximal stimulation from stacking ceiling doses.
Frequently Asked Questions
CJC-1295 with DAC is typically dosed at 100–500mcg per injection, with 200–300mcg being the most common research protocol range. This dose is administered 1–3 times per week depending on research objectives. CJC-1295 without DAC (Modified GRF 1-29) is dosed lower at 100–200mcg per injection but requires 1–3 daily injections due to its 30-minute half-life. The formulation determines both dose per injection and frequency.
No — CJC-1295 with DAC should not be dosed daily because its 6–8 day half-life from albumin binding makes weekly or bi-weekly administration the correct protocol. Daily micro-dosing fragments the sustained GH amplification mechanism and prevents stable plasma elevation. The DAC modification was specifically designed to eliminate daily dosing requirements. If daily administration is required for research design, use CJC-1295 without DAC (Modified GRF 1-29) instead.
The saturation dose for CJC-1295 with DAC is approximately 1mcg per kilogram of body weight, beyond which GHRH receptor occupancy plateaus and additional peptide produces diminishing returns. For a 75kg research model, saturation occurs around 75mcg, though most protocols use 200–500mcg to account for individual receptor density variation. Doses above 500mcg per injection rarely produce proportional increases in IGF-1 elevation and increase injection site reaction incidence without additional benefit.
Reconstituted CJC-1295 must be refrigerated at 2–8°C immediately after mixing with bacteriostatic water and used within 28 days to prevent peptide degradation. Lyophilised powder (unreconstituted) should be stored at −20°C and can remain stable for 12–24 months under proper conditions. Temperature excursions above 8°C for reconstituted peptide cause irreversible amino acid chain degradation that cannot be detected visually — if CJC-1295 is left unrefrigerated overnight, it should not be used for research requiring precise dosing.
If you miss a CJC-1295 with DAC injection by fewer than five days, administer the missed dose as soon as you remember and resume your regular schedule from that new injection date. CJC-1295’s 6–8 day half-life means plasma levels remain elevated for several days after a missed dose. Missing an injection by more than five days (beyond the half-life window) requires restarting at a conservative dose of 100–200mcg to avoid acute receptor overstimulation after clearance.
Yes — CJC-1295 is frequently combined with GHRPs like Ipamorelin, GHRP-2, or GHRP-6 to create synergistic GH release through complementary receptor pathways. Standard protocols dose CJC-1295 with DAC at 200–300mcg twice weekly alongside a GHRP at 200–300mcg 1–3 times daily. The combination produces additive GH elevation 40–60% higher than CJC-1295 alone in research models. Start with CJC-1295 alone for 4–6 weeks before adding a GHRP to isolate each compound’s contribution.
CJC-1295 with DAC contains a Drug Affinity Complex that binds to serum albumin, extending half-life to 6–8 days and allowing weekly dosing. CJC-1295 without DAC (Modified GRF 1-29) lacks this modification and is cleared within 30 minutes, requiring multiple daily injections. The DAC version creates sustained baseline GH elevation; the non-DAC version mimics pulsatile secretion. They are functionally different peptides with opposite dosing protocols despite sharing the CJC-1295 name.
Plasma IGF-1 elevation — the primary downstream marker of sustained GH activity — typically becomes measurable 7–14 days after starting CJC-1295 with DAC at 200–300mcg twice weekly. Peak IGF-1 levels stabilise after 3–4 weeks of consistent dosing as steady-state plasma concentration is reached. Observable physiological changes (body composition shifts, recovery metrics) lag IGF-1 elevation by 4–8 weeks in most research models. Non-DAC formulations produce acute GH spikes within 30–60 minutes of administration but require weeks of consistent dosing for cumulative downstream effects.
CJC-1295 with DAC has been used in research protocols extending 6–12 months with acceptable safety profiles when dosed at 200–300mcg twice weekly. The primary risk is GHRH receptor desensitisation from chronic stimulation, which is why cycling protocols (8 weeks on, 4 weeks off) preserve receptor sensitivity better than continuous administration. Injection site reactions, transient water retention, and mild carpal tunnel symptoms are the most common adverse effects. Long-term safety data beyond 12 months is limited — most published research involves shorter intervention periods.
CJC-1295 is administered via subcutaneous injection into fatty tissue, typically in the abdomen 2–3 inches from the navel or the outer thigh. Use a 29–31 gauge insulin syringe, pinch the injection site to create a skin fold, insert the needle at a 45-degree angle, and inject slowly over 5–10 seconds. Rotate injection sites with each dose to prevent localised lipohypertrophy or scarring. Subcutaneous administration allows the peptide to enter systemic circulation gradually; intramuscular injection is not recommended as it alters absorption kinetics.
CJC-1295 is classified as a research peptide and is not FDA-approved for human therapeutic use outside clinical trials. It is legally available for laboratory research purposes through suppliers like Real Peptides that operate under appropriate regulatory frameworks. Research institutions and laboratories must maintain proper documentation, institutional review protocols, and biosafety compliance when working with investigational peptides. Individual researchers should consult institutional guidelines and applicable regulations in their jurisdiction before initiating peptide research protocols.
Dosing CJC-1295 before bed aligns peptide administration with the body’s natural nocturnal GH surge, which occurs 60–90 minutes after sleep onset. For CJC-1295 with DAC, timing matters less because the extended half-life maintains elevated GH throughout the 24-hour cycle regardless of administration time. For non-DAC formulations (Modified GRF 1-29), pre-sleep dosing amplifies the strongest endogenous GH pulse of the day, maximising synergistic effect. Research models show slightly higher IGF-1 response when GH secretagogues are timed to circadian GH peaks versus random administration times.